Calculated cumulative incidence from current age to 70 years, for any subsequent cancer or for colorectal cancer as a subsequent cancer at 70 years by patient's current age and genetic variant, and comparison with corresponding incidences previously reported in patients who had not had cancer before inclusion
| Cumulative incidence for any subsequent cancer at 70 years (95% CI) | Cumulative incidence for colorectal as subsequent cancer at 70 years (95% CI) | |||||
|---|---|---|---|---|---|---|
| Current age (years) | path_MLH1 | path_MSH2 | path_MSH6 | path_MLH1 | path_MSH2 | path_MSH6 |
| Patients with LS having had previous cancer(s) (this report) | ||||||
| 40 | 73% (66.9% to 79.2%) | 76% (68.8% to 82.6%) | 50% (33.8% to 66.5%) | 46% (37.7% to 54.4%) | 48% (38.1% to 58.1%) | 23% (7.4% to 37.9%) |
| 50 | 65% (57.9% to 72.1%) | 63% (54.1% to 71.8%) | 47% (30.6% to 62.5%) | 38% (29.2% to 45.9%) | 35% (24.5% to 44.9%) | 23% (7.4% to 37.9%) |
| 60 | 47% (38.2% to 56.0%) | 42% (30.8% to 52.8%) | 31% (15.4% to 47.0%) | 24% (15.8% to 32.2%) | 18% (8.2% to 27.3%) | 13% (0.7% to 25.1%) |
| Patients with LS without previous cancer* | ||||||
| 40 | 66% (57.8% to 74.2%) | 67% (55.8% to 77.8%) | 53% (38.6% to 68.6%) | 37% (30.1% to 49.4%) | 28% (15.2% to 41.2%) | 20% (4.4% to 35.4%) |
| 50 | 53% (41.9% to 63.6%) | 55% (40.4% to 69.0%) | 43% (26.4% to 60.2%) | 25% (18.0% to 39.6%) | 21% (6.9% to 34.1%) | 18% (2.8% to 33.8%) |
| 60 | 32% (17.7% to 45.4%) | 33% (14.4% to 51.5%) | 24% (5.6% to 42.2%) | 13% (4.5% to 27.1%) | 14% (0.6% to 27.6%) | 11% (2.8% to 33.8%) |
| Relative cumulative incidence† patients with LS having had previous cancer(s) | ||||||
| 40 | 1.11 (0.96 to 1.29) | 1.13 (0.95 to 1.38) | 0.94 (0.60 to 1.44) | 1.26 (0.93 to 1.77) | 1.70‡ (1.09 to 3.24) | 1.14 (0.33 to 5.47) |
| 50 | 1.23 (0.99 to 1.59) | 1.15 (0.87 to 1.60) | 1.09 (0.63 to 1.91) | 1.50 (0.98 to 2.65) | 1.69 (0.91 to 5.16) | 1.23 (0.35 to 8.40) |
| 60 | 1.49 (0.98 to 2.71) | 1.27 (0.74 to 2.97) | 1.29 (0.53 to 5.76) | 1.80 (0.88 to 8.62) | 1.26 (0.46 to 30.82) | 1.17 (0.06 to ∞) |
*Calculated from online table in Møller et al 2015.3
†Cumulative incidence in this report divided by cumulative incidence in patients with LS without previous cancer.3
‡None of the cumulative incidences compared besides this one were significantly different (p<0.05).
LS, Lynch syndrome.